Completed PHASE1 INTERVENTIONAL 4-arm NCT01999231

Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Sponsor: Air Force Military Medical University, China

Conditions Healthy

Interventions ESAT6-CFP10

Updated 9 times since 2017 Last updated: Mar 26, 2015 Started: Sep 30, 2013 Primary completion: Oct 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Air Force Military Medical University, China and has accumulated 9 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Dec 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE1
Nov 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Nov 2020 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Air Force Military Medical University, China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Proswell Medical Corporation
Shanghai Public Health Clinical Center

Data source: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.